Filing Flows › Viridian Therapeutics (VRDN) › Stock forecast & fair value
Viridian Therapeutics (VRDN) stock forecast and price target
Viridian Therapeutics (VRDN) trades at $28.49. 15 analysts' median price target is $35.00 (+23%), from $22.00 to $50.00.
Viridian Therapeutics' latest quarter
Viridian Therapeutics, Q3 2026: revenue $25.8M (-64% year over year), operating margin -401.8%, net loss $101M, operating cash flow −$92.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for VRDN stock?
The median of 15 analysts' 12-month targets is $35.00, +23% from $28.49; the range is $22.00 to $50.00. The average rating is strong buy.
Does Viridian Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 60% of the quarters on record.
Is VRDN stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.